09 August 2017
|
min read
This profile from the Australian Financial Review highlights how Professor Peter Donnelly’s work in genomics and statistical modelling is poised to help pharmaceutical companies streamline drug development and cut costs dramatically.
This article was originally published in Financial Review on 8 August 2017.
